CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

  • STATUS
    Not Recruiting
  • End date
    Sep 30, 2022
  • participants needed
    416
  • sponsor
    Calithera Biosciences, Inc
Updated on 23 January 2021
Investigator
Clinical Administrator
Primary Contact
MacQuarie University Hospital (1.3 mi away) Contact
+138 other location
measurable disease
vegf
cabozantinib
nivolumab
ipilimumab
vascular endothelial growth factor

Summary

This clinical trial is a randomized Phase 2 evaluation of CB-839 (telaglenastat) in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell Carcinoma with a clear cell component.

Description

This clinical trial is a randomized Phase 2 evaluation of CB-839 (telaglenastat) in combination with cabozantinib versus placebo with cabozantinib in Renal Cell Carcinoma patients with at least one and not more than 2 prior therapies in the advanced or metastatic setting.

Details
Condition Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
Treatment Placebo, Cabozantinib, CB-839
Clinical Study IdentifierNCT03428217
SponsorCalithera Biosciences, Inc
Last Modified on23 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note